Results 141 to 150 of about 21,696 (215)

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

<i>Mycobacterium avium</i> Complex Pulmonary Disease as a Clinical Signal of Host Vulnerability in Advanced Myelofibrosis. [PDF]

Clin Case Rep
Sekiya M, Yekuno K, Ghumare I, Margulis M.   +3 more
europepmc   +1 more source

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, restores blood–brain barrier integrity in a human stem cell‐based model of ischaemic stroke

British Journal of Pharmacology, Volume 183, Issue 19, Page 5791-5812, October 2026.
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó, Koppány Párdi, Zuhao Cui, Gergő Porkoláb, Zsófia Hoyk, Csilla Kovács, Janet F. Adegbite, Virág Fodor, Nárcisz M. Cser, László Dér, Krisztina Nagy, Csilla Sajben, Roland Tengölics, Mária A. Deli, Szilvia Veszelka   +14 more
wiley   +1 more source

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. [PDF]

Lancet Haematol
Markova A, Ostojić J, Rotemberg V, Nykaza I, Kanbar J, Papadopoulos EB, Dusza S, Ai R, Maier T, Lacouture ME, Tamari R, Shaffer BC, Scordo M, Perales MA, Harris A, Ponce DM.   +15 more
europepmc   +1 more source

Myelofibrosis: Treatment Options After Ruxolitinib Failure

While allogeneic hematopoietic stem cell transplantation remains the only curative therapy for patients with myelofibrosis, its applicability is limited both by the high morbidity and mortality associated with the procedure and by the fact that only a ...
Adrián Segura Díaz, María Teresa Gómez-Casares, Ruth Stuckey   +2 more
core   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, Volume 56, Issue 10, Page 1162-1176, October 2026.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, Volume 117, Issue 4, Page 739-749, October 2026.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor-Induced bullous pemphigoid. [PDF]

JAAD Case Rep
Lederbogen I, Meier-Schiesser B.
europepmc   +1 more source

RuBi-Ruxolitinib: a photoreleasable antitumor JAK inhibitor

We describe the synthesis and biological testing of ruthenium-bipyridine ruxolitinib (RuBiRuxo), a photo-releasable form of ruxolitinib, a JAK inhibitor used as an antitumoral agent in cutaneous T-cell lymphomas (CTCL).
Etchenique, Roberto, Palomero, Teresa, Rafic, Estefanía Constanza, Ma, Cindy, Shih, Bobby B., Etchenique, Roberto Argentino, Miller, Hannah, Yuste, Rafael, Rafic, Estefania   +8 more
core   +1 more source